Carisma Therapeutics INC. 8-K Filing
Ticker: CARM · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1485003
Sentiment: neutral
Filing Stats: 1,470 words · 6 min read · ~5 pages · Grade level 12.6 · Accepted 2025-12-05 16:02:33
Key Financial Figures
- $0.001 — ge on which registered* Common Stock, $0.001 par value per share CARM The Nasdaq
- $350 — 2025 and will be compensated at rate of $350 per hour. For a description of Mr. Kell
- $50,000 — ses. The Company will pay Mr. Jalbert $50,000 per year of service, pursuant to a lett
Filing Documents
- tm2532811d1_8k.htm (8-K) — 33KB
- 0001104659-25-118863.txt ( ) — 198KB
- carm-20251204.xsd (EX-101.SCH) — 3KB
- carm-20251204_lab.xml (EX-101.LAB) — 33KB
- carm-20251204_pre.xml (EX-101.PRE) — 22KB
- tm2532811d1_8k_htm.xml (XML) — 4KB
02 Departure of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Executive Officer On December 5, 2025, Natalie McAndrew notified the Company of her decision to resign as Vice President of Finance, Treasurer and Secretary of the Company, effective as of December 31, 2025. The resignation was not a result of any disagreement with the Company's operations, policies or practices. Appointment of Executive Officers and Director On December 4, 2025, the Board appointed Steven Kelly to serve as the interim Chief Executive Officer of the Company on a consulting basis, effective immediately. In connection with his appointment, Mr. Kelly was designated as the Company's principal executive officer. On December 4, 2025, the Company also entered into a Consulting Agreement with Mr. Kelly (the "Consulting Agreement"), pursuant to which he will serve as the Company's interim Chief Executive Officer until December 31, 2025 and will be compensated at rate of $350 per hour. For a description of Mr. Kelly's biography, refer to the Company's Amendment No. 1 to the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 29, 2025. On December 4, 2025, the Board appointed Craig R. Jalbert to serve as the Chief Executive Officer, President, Treasurer and Secretary of the Company, effective as of January 1, 2026, to succeed Mr. Kelly and to assist with the Company's remaining wind down activities. In connection with his appointment, Mr. Jalbert was appointed as the Company's principal executive officer, principal financial officer and principal accounting officer, effective as of January 1, 2026. On December 4, 2025, the Board also appointed Mr. Jalbert as a director, effective as of January 1, 2026. Mr. Jalbert, age 64, has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By: /s/ Steven Kelly Date: December 5, 2025 Steven Kelly Interim Chief Executive Officer